Karyopharm Therapeutics Inc. Common Stock (KPTI) Stock Price Today & Analysis
Valuation
Earnings Per Share
Income Statement
Dividend
Solvency
About Karyopharm Therapeutics Inc. Common Stock
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
FAQ
- Download the Gotrade app from the App Store or Google Play.
- Create an account and complete KYC.
- Make a deposit.
- Search for the code "KPTI", then tap "Trade".
- Tap the "Buy" button.
- Enter the amount you want to buy. You have two options:
- Buy KPTI by number of shares.
- Buy fractional shares in dollars, starting from $1.
- Swipe up to confirm your order—done!
- Compare valuation (e.g., P/E, P/S) against historical averages or competitors.
- Review revenue and earnings growth.
- Check margins and cash flow.
- Evaluate business outlook and the company's position within its industry.





